Research and Publications:

Bio: Ms. Mikhail has co-founded of seven University biotech spin-outs (University of North Carolina - Chapel Hill, Harvard University, Mt. Sinai, University of Chicago, and Duke) and has continued active involvement in each. One company, Chatham Therapeutics, Inc, was bought by Baxter in 2013. Another, Boston Immune Technologies & Therapeutics, Inc. (BITT) is in the process of being sold to a Big Pharma. A third company, Asklepios BioPharmaceutical, Inc, is one of the longest existing rAAV gene therapy companies, and recently spun off a new company, Bamboo Therapeutics, Inc., of which Ms. Mikhail is the CEO. She is an attorney by training, with a law degree from Northwestern University and an MBA from the University of Chicago. Ms. Mikhail worked for Ropes & Gray in Boston, and ran her own firm, Life Sciences Law, PLLC (LSL) in Research Triangle Park, NC, for 13 years before retiring from the practice of law at the end of last year. The firm advised some of the world's largest biotech and pharmaceutical companies such as Bayer, GSK, and Sanofi. Ms. Mikhail previously worked as a management consultant for A.T. Kearney and Arthur Andersen, where she advised several of the Fortune 100 on operational and strategic matters.